Moderately to Severely Active Ulcerative Colitis (DBCOND0105407)

Identifiers

Synonyms

Not Available

Associated Data

Indicated Drugs and Targets

Drug	Description	Targets
Adalimumab	A monoclonal anti-tumor necrosis factor alpha antibody used in the treatment of a wide variety of inflammatory conditions such as rheumatoid arthritis, Crohn's disease, and ankylosing spondylitis.	Tumor necrosis factortarget
Filgotinib	A Janus kinase (JAK) 1 selective inhibitor used to treat cases of rheumatoid arthritis that are unresponsive to conventional treatments.	Tyrosine-protein kinase JAK1target Cocaine esteraseenzyme Liver carboxylesterase 1enzyme ATP-dependent translocase ABCB1transporter
Infliximab	A monoclonal anti tumor necrosis factor alpha antibody used in the treatment of a wide variety of inflammatory conditions such as rheumatoid arthritis, Crohn's disease, and ankylosing spondylitis.	Tumor necrosis factortarget
Mirikizumab	An anti-IL-23 monoclonal antibody used as a second-line therapy for moderate-to-severe active ulcerative colitis.	Interleukin-23 subunit alphatarget
Ozanimod	A sphingosine 1-phosphate receptor modulator being studied to treat Multiple Sclerosis (MS) and inflammatory bowel disease (IBD).	Sphingosine 1-phosphate receptor 1target Sphingosine 1-phosphate receptor 5target Amine oxidase [flavin-containing] Btransporter Broad substrate specificity ATP-binding cassette transporter ABCG2transporter ATP-dependent translocase ABCB1transporter Aldehyde dehydrogenase family 3 member A2enzyme Alcohol dehydrogenase class-3enzyme Arylamine N-acetyltransferase 2enzyme Cytochrome P450 2C8enzyme Amine oxidase [flavin-containing] Benzyme Aldo-keto reductase family 1 member C1enzyme Aldo-keto reductase family 1 member C2enzyme Cytochrome P450 3A4enzyme
Upadacitinib	An oral Janus kinase (JAK)1-selective inhibitor used in the treatment of moderate to severe rheumatoid arthritis, active psoriatic arthritis, ankylosing spondylitis, and severe atopic dermatitis, including in patients who did not respond well to other therapies.	Tyrosine-protein kinase JAK1target Cytochrome P450 3A4enzyme Cytochrome P450 2D6enzyme ATP-dependent translocase ABCB1transporter Broad substrate specificity ATP-binding cassette transporter ABCG2transporter Solute carrier organic anion transporter family member 1B1transporter
Vedolizumab	An integrin blocker and anti-inflammatory agent used to manage ulcerative colitis and Crohn's disease in adults.	Integrin alpha-4target Integrin beta-7target

Clinical Trials

Identifier	Title	Drug(s)	Purpose	Phase	Status
NCT06588855	A Study to Assess the Efficacy and Safety of Induction Therapy With RO7790121 in Participants With Moderately to Severely Active Ulcerative Colitis	RVT-3101	treatment	3	recruiting
NCT06589986	A Study to Assess the Efficacy and Safety of RO7790121 for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis	RVT-3101	treatment	3	recruiting
NCT04176588	A Phase 3 Study of Etrasimod in Subjects With Moderately to Severely Active Ulcerative Colitis	Etrasimod	treatment	3	active_not_recruiting
NCT03221036	Efficacy and Safety of Vedolizumab IV in Chinese Participants With Ulcerative Colitis	Vedolizumab	treatment	3	recruiting